Ebola virus disease (EVD), also known as Ebola hemorrhagic fever (EHF), results from Ebola virus and three other closely related viruses in the genes (group of related viruses) of ebola virus. Initial symptoms of this disease include sore throat, headaches, fever and muscles pain. It causes hemorrhagic fever that leads to internal or external bleeding. EVD is widely prevalent in Central and Western Africa, and near tropical rainforests. Due to high mortality rate and unavailability of effective treatments, the pharmaceutical companies have big opportunities to explore.

1. Global Potential Analysis of Ebola drug and Vaccines Market
Published Date:30 September 2014 No. of pages : 55

2. Ebolavirusdisease(EVD),alsoknownasEbolahemorrhagicfever(EHF),resultsfromEbolavirusandthreeothercloselyrelatedvirusesinthegenes(groupofrelatedviruses)ofebolavirus.Initialsymptomsofthisdiseaseincludesorethroat,headaches,feverandmusclespain.Itcauseshemorrhagicfeverthatleadstointernalorexternalbleeding.EVDiswidelyprevalentinCentralandWesternAfrica,andneartropicalrainforests.
Duetohighmortalityrateandunavailabilityofeffectivetreatments,thepharmaceuticalcompanieshavebigopportunitiestoexplore.TekmiraPharmaceuticals,BioCrystPharmaceuticalInc.,SerepataTherapeutics,NewLinkGeneticsandMappBiopharmaceuticalaresomeoftheleadingcompaniesfocusingonresearchactivitiestodevelopefficaciousmedicineforEVD.
Introduction to Ebola drug and Vaccines Market

3. Additionally,thegovernmentsinthedevelopedcountrieshavealsotakenformidablestepstosupporttheresearchactivitiesforthedevelopmentofEVDtherapeuticsbyprovidingfundingandfloatingfavorablepolicies.Asanexample,TekmiraPharmaceuticalshasreceivedfast-trackdesignationfromU.S.foodanddrugadministrationfortheiranti-ebolatherapeuticTKM-ebola.In2012,SareptaTherapeuticshadalsoreceivedfasttrackdesignationforAVI-7537,aleaddrugcandidateforEVD.Boththesecompaniesaredevelopingtheiranti-ebolaproductsunderthecontractoftheU.S.departmentofdefense(DoD).
EbolatherapeuticsandvaccinesmarketissegmentedonthebasisofgeographyintoNorthAmerica,Europe,Asia-pacificandLAMEA.EVDisrampantinLAMEAregions,specificallyinAfricancountries.Thisisapositivesignforpharmaceuticalcompanies,portrayingahighlylucrativemarketinthefuture.Earlier,USgovernmentdidnothaveanyregulationsforEVDtherapeuticsduetonegligibleincidencesofthisdiseaseindevelopedeconomies.However, preferenceofAfricanpeopletomigratetodevelopedeconomiesratherthandevelopingeconomieshascautionedthegovernmentsinthedevelopedeconomies,leadingtoformulateregulationsinordertocurbthespreadofthisdisease.
Introduction to Ebola drug and Vaccines Market

4. Introduction
Scope of the Report
Key Benefits
Key Audiences

5. KEY BENEFITS
Totrackcommercialtrends,majorclinicaltrialsandtheirstatusarepursuedofclosely
Thereportshedslightonthekeyeventsheldinpastyearsconcerningthedevelopmentofebolaviraldiseasetherapeutics
Pin-pointanalysisofgeographicsegmentshelpstoidentifyopportunitiesforgrowthwithintheebolatherapeuticsandvaccinesmarket
Porter’sFiveForcesanalysisexaminesthecompetitivestructureoftheebolatherapeuticsandvaccinesmarketandwouldassistmarketstrategistsintheirrespectivedecisionmakingprocess
In-depthcoverageoftheebolatherapeuticsandvaccinesmarketincludingdrivers,restraintsandopportunitieswouldhelpprofessionalstobetterunderstandmarketbehaviour
Detailedstudyofthestrategiesofkeyleaders,partnershipsandacquisitionsintheebolatherapeuticsandvaccinesmarketwouldbeinformativeforprofessionalsincorporatesector

6. Table of Contents
1.INTRODUCTION
2.EXECUTIVE SUMMARY
3.MARKET OVERVIEW
4.FORECAST SCENARIO ANALYSIS OF EBOLA VACCINES, 2013-2020,
5.GLOBAL PIPELINE AND MARKET POTENTIAL ANALYSIS OF EBOLA THERAPEUTIC VACCINES MARKET BY GEOGRAPHY
6.COMPANY PROFILE

7. Global Potential Analysis of Ebola drug and Vaccines Market Overview
1.Market Definition and Scope
2.Key Findings
3.Key market player positioning
4.Ebola Virus Key Facts
5.Amend for anti-Ebola disease drugs in United States
6.Guidance on Air Medical Transport for Patients with Ebola Virus Disease
7.“Fast Track” designation to Anti-E bola drugs research from the U.S. government
8.ZMMP Drug: An Orphan solution for E-bola viral disease
9.Ethical Dilemmas from therapeutics
10.TekmiraPharma received boost to ebolaR&D through FDA fundings
11.Clinical Trials
12.Market Dynamics

8. MARKET DYNAMICS
Key Market Drivers
Prevalent cases and unpredictable nature of disease
Increased rate of migration from developing countries
Lack of relevant medication

9. MARKET DYNAMICS
High initial investment for R&D
Key Market Restraints
Obstractiveethical considerations.

10. FORECASTE SCENARIO ANALYSIS OF EBOLA VACCINES, 2013-202
Moderate growth scenario
Diminishing growth scenario
Rapid growth scenario

11. GLOBAL PIPELINE AND MARKET POTENTIAL ANALYSIS OF E- BOLA THERAPEUTIC VACCINES MARKET BY GEOGRAPHY
North America,Europe, Asia Pacific, LAMEA

12. Company Profiles
1.TekmiraPharmaceuticals
2.BioCrystPharmaceutical Inc
3.SerepataTherapeutics
4.NewLinkGenetics Corp.
5.MappBiopharmaceutical

13. Follow Us On
Thank You!
For More Details
Visit us at
http://www.alliedmarketresearch.com/ebola-therapeutics- vaccines-market